"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
Concept/Terms
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in Harvard Catalyst Profiles by year, and whether "Antitubercular Agents" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 1 | 0 | 1 |
1996 | 4 | 3 | 7 |
1997 | 2 | 4 | 6 |
1998 | 2 | 0 | 2 |
1999 | 5 | 5 | 10 |
2000 | 5 | 2 | 7 |
2001 | 6 | 4 | 10 |
2002 | 2 | 2 | 4 |
2003 | 9 | 1 | 10 |
2004 | 14 | 5 | 19 |
2005 | 11 | 8 | 19 |
2006 | 16 | 5 | 21 |
2007 | 11 | 2 | 13 |
2008 | 13 | 5 | 18 |
2009 | 11 | 3 | 14 |
2010 | 18 | 12 | 30 |
2011 | 24 | 14 | 38 |
2012 | 42 | 15 | 57 |
2013 | 28 | 13 | 41 |
2014 | 29 | 13 | 42 |
2015 | 37 | 12 | 49 |
2016 | 38 | 16 | 54 |
2017 | 37 | 20 | 57 |
2018 | 27 | 15 | 42 |
2019 | 36 | 16 | 52 |
2020 | 22 | 30 | 52 |
2021 | 16 | 40 | 56 |
2022 | 6 | 36 | 42 |
2023 | 4 | 20 | 24 |
2024 | 1 | 3 | 4 |
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis. Clin Infect Dis. 2024 Feb 17; 78(2):269-276.
-
Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho. Glob Health Action. 2024 Dec 31; 17(1):2305930.
-
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs. Clin Infect Dis. 2024 Jan 25; 78(1):144-148.
-
Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up. Clin Infect Dis. 2024 Jan 25; 78(1):164-171.
-
Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia. Sci Rep. 2024 01 04; 14(1):508.
-
Addressing patients' unmet needs related to multidrug-resistant tuberculosis (MDR-TB) care: A qualitative research study from Pune city, India. PLoS One. 2023; 18(12):e0295508.
-
Screening with GenoType® MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes. Int J Tuberc Lung Dis. 2023 Dec 01; 27(12):949-951.
-
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials. 2023 Nov 30; 24(1):773.
-
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023 11 15; 67(11):e0073723.
-
COVID-19 in Patients with Drug-Resistant Tuberculosis in Lesotho. Am J Trop Med Hyg. 2023 10 09; 109(5):1205-1206.